|
186 Products |
| 186 Products |
|
1696 Diseases |  |
94663 News |  |
| «12...10371038103910401041104210431044104510461047...10631064» |
- Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
Combination therapy: Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma (clinicaltrials.gov) - May 21, 2013
P0, N=15, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- | mometasone furoate nasal spray / Generic mfg.
New P4 trial: Intranasal Steroids for the Treatment of Nocturnal Enuresis With Associated Obstructive Sleep Apnea (clinicaltrials.gov) - May 21, 2013
P4, N=65, Recruiting, Sponsor: University of Alberta
- azacitidine / Generic mfg.
New P1 trial, Combination therapy: A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML (clinicaltrials.gov) - May 21, 2013
P1, N=22, Recruiting, Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
- montelukast / Generic mfg., fluticasone / Generic mfg.
Enrollment change: The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis (clinicaltrials.gov) - May 20, 2013
P4, N=102, Terminated, Sponsor: University of Chicago
N=80 --> 102
- Ultibro (glycopyrronium/indacaterol) / Novartis
New P3 trial: A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD (clinicaltrials.gov) - May 20, 2013
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
- Decadron (dexamethasone) / Merck (MSD)
Trial termination: Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy (clinicaltrials.gov) - May 20, 2013
P2, N=7, Terminated, Sponsor: University of South Florida
N=80 --> 102 Completed --> Terminated; Closed due to poor accrual and lack of feasibility to finish study per DSMB
- Decadron (dexamethasone) / Merck (MSD)
Enrollment change: Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy (clinicaltrials.gov) - May 20, 2013
P2, N=7, Terminated, Sponsor: University of South Florida
Completed --> Terminated; Closed due to poor accrual and lack of feasibility to finish study per DSMB N=180 --> 7
- | melphalan / Generic mfg.
Enrollment change: SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma (clinicaltrials.gov) - May 20, 2013
P3, N=899, Completed, Sponsor: Southwest Oncology Group
N=180 --> 7 N=500 --> 899
- cytarabine / Generic mfg.
New P2 trial: Etude de phase II évaluant l'association doxorubicine liposomale non-pégylée-dexaméthasone chez des patients immunocompétents présentant un lymphome cérébral réfractaire ou en rechute à une première ligne de chimiothérapie par méthotrexate à haute dose (MTXHD) et/ou cytarabine à forte dose. (EUDRACT) - May 20, 2013
P2, N=25, Ongoing, Sponsor: CHRU de Brest
- | melphalan / Generic mfg.
Trial completion: SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma (clinicaltrials.gov) - May 20, 2013
P3, N=899, Completed, Sponsor: Southwest Oncology Group
N=500 --> 899 Active, not recruiting --> Completed
- ||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Combination therapy: SUNDIAL: A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - May 19, 2013
P3, N=578, Completed, Sponsor: Genentech
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||| Ninlaro (ixazomib) / Takeda
Enrollment open: TOURMALINE-MM2: IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - May 19, 2013
P3, N=701, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Uceris (budesonide rectal foam) / Bausch Health, Dr Falk, Kissei, Ajinomoto
Enrollment change: Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis (clinicaltrials.gov) - May 16, 2013
P3, N=281, Completed, Sponsor: Salix Pharmaceuticals
Not yet recruiting --> Recruiting N=430 --> 281
- ||||| Uceris (budesonide rectal foam) / Bausch Health, Dr Falk, Kissei, Ajinomoto
Enrollment change: Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis (clinicaltrials.gov) - May 16, 2013
P3, N=265, Completed, Sponsor: Salix Pharmaceuticals
N=430 --> 281 N=430 --> 265
- ||||||| Uceris (budesonide rectal foam) / Bausch Health, Dr Falk, Kissei, Ajinomoto
Trial completion: Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis (clinicaltrials.gov) - May 16, 2013
P3, N=281, Completed, Sponsor: Salix Pharmaceuticals
N=430 --> 265 Recruiting --> Completed
- ||||||| Uceris (budesonide rectal foam) / Bausch Health, Dr Falk, Kissei, Ajinomoto
Trial completion: Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis (clinicaltrials.gov) - May 16, 2013
P3, N=265, Completed, Sponsor: Salix Pharmaceuticals
Recruiting --> Completed Recruiting --> Completed
- Decadron (dexamethasone) / Merck (MSD)
Trial withdrawal: Plasma Glucose Levels With Dexamethasone as Adjuvant to Interscalene Block (clinicaltrials.gov) - May 16, 2013
P3, N=0, Withdrawn, Sponsor: Lifespan
Recruiting --> Completed Not yet recruiting --> Withdrawn
- Decadron (dexamethasone) / Merck (MSD)
Enrollment change: Plasma Glucose Levels With Dexamethasone as Adjuvant to Interscalene Block (clinicaltrials.gov) - May 16, 2013
P3, N=0, Withdrawn, Sponsor: Lifespan
Not yet recruiting --> Withdrawn N=100 --> 0
- ||||| cisplatin / Generic mfg., cyclophosphamide / Generic mfg.
New P2 trial: Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy (clinicaltrials.gov) - May 16, 2013
P2, N=315, Not yet recruiting, Sponsor: Acacia Pharma Ltd
- | cyclophosphamide / Generic mfg., carfilzomib / Generic mfg.
Clinical: Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd) (clinicaltrials.gov) - May 16, 2013
P1/2, N=71, Recruiting, Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
- | dexamethasone / Generic mfg., clomifene citrate / Generic mfg.
New P4 trial: Ovulation Induction With Clomiphene Citrate and Dexamethasone (clinicaltrials.gov) - May 15, 2013
P4, N=140, Recruiting, Sponsor: San Antonio Military Medical Center
- | Rituxan (rituximab) / Roche
New P2 trial: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - May 15, 2013
P2, N=300, Recruiting, Sponsor: National Cancer Institute (NCI)
- ||| PF-06291874 / Pfizer
New P1 trial: PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients (clinicaltrials.gov) - May 15, 2013
P1, N=117, Completed, Sponsor: Pfizer
- | salmeterol/fluticasone easyhaler / Orion Corp
New P1 trial: Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler With Seretide Diskus (clinicaltrials.gov) - May 15, 2013
P1, N=48, Completed, Sponsor: Orion Corporation, Orion Pharma
- ||||||| Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
Trial completion: A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma (clinicaltrials.gov) - May 15, 2013
P3, N=243, Completed, Sponsor: GlaxoSmithKline
N=100 --> 0 Active, not recruiting --> Completed
- Nasonex (mometasone furoate nasal spray) / Merck (MSD)
Biomarker, Trial initiation date, IO biomarker: MERK2: An Open-label Study to Identify Molecular Markers of Steroid Resistance (clinicaltrials.gov) - May 14, 2013
P4, N=24, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Initiation date: Sep 2012 --> Jul 2013
- BHQ880 / Novartis, MorphoSys
Enrollment change: Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency (clinicaltrials.gov) - May 14, 2013
P2, N=9, Completed, Sponsor: Novartis Pharmaceuticals
Initiation date: Sep 2012 --> Jul 2013 N=12 --> 9
- Avastin (bevacizumab) / Roche
Enrollment closed: Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma (clinicaltrials.gov) - May 14, 2013
P2, N=39, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=12 --> 9 Recruiting --> Active, not recruiting
- | dexamethasone / Generic mfg., lenalidomide / Generic mfg., dasatinib / Generic mfg.
Trial completion, Combination therapy: Dasatinib in Combination With Revlimid (and Dexamethasone) (clinicaltrials.gov) - May 14, 2013
P1, N=35, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- prednisone delayed-release tablet / Generic mfg.
Enrollment closed, Metastases: Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis (clinicaltrials.gov) - May 13, 2013
P1, N=10, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Enrollment change: Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease (clinicaltrials.gov) - May 12, 2013
P3, N=1734, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting N=1000 --> 1734
- | bortezomib / Generic mfg., dexamethasone injection / Generic mfg., doxorubicin hydrochloride / Generic mfg.
New P2 trial: A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - May 12, 2013
P2, N=72, Recruiting, Sponsor: Shanghai Changzheng Hospital
- || paricalcitol / Generic mfg.
Trial initiation date: Oral Paricalcitol in Kidney Transplant Recipients (clinicaltrials.gov) - May 8, 2013
P=N/A, N=100, Completed, Sponsor: Mayo Clinic
N=1000 --> 1734 Initiation date: Feb 2006 --> Jan 2007
- fluticasone / Generic mfg.
Trial completion: ReHICS: Repeated High-dose Inhaled Corticosteroids for Asthma (clinicaltrials.gov) - May 8, 2013
P2, N=20, Completed, Sponsor: Johns Hopkins University
Initiation date: Feb 2006 --> Jan 2007 Active, not recruiting --> Completed
- |||| oprozomib (ONX 0912) / Amgen
Clinical: Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - May 8, 2013
P1/2, N=128, Recruiting, Sponsor: Onyx Therapeutics, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- budesonide/formoterol / Generic mfg.
Enrollment closed: Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma (clinicaltrials.gov) - May 8, 2013
P4, N=40, Active, not recruiting, Sponsor: Children's Hospital Boston
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
Trial completion: A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects (clinicaltrials.gov) - May 8, 2013
P1, N=44, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||||||||| Ninlaro (ixazomib) / Takeda
New P3 trial: TOURMALINE-MM2: IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - May 7, 2013
P3, N=701, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
- Decadron (dexamethasone) / Merck (MSD)
New P2 trial: Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma (clinicaltrials.gov) - May 7, 2013
P2, N=41, Recruiting, Sponsor: University of Iowa
- triamcinolone acetonide / Generic mfg.
Enrollment closed: Effect of Steroid Injections in a Knee With Osteoarthritis (clinicaltrials.gov) - May 6, 2013
P4, N=140, Active, not recruiting, Sponsor: Tufts Medical Center
Recruiting --> Completed Recruiting --> Active, not recruiting
- cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change: Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer (clinicaltrials.gov) - May 6, 2013
P=N/A, N=41, Completed, Sponsor: University of Washington
Recruiting --> Active, not recruiting N=57 --> 41
- Oncaspar liquid (pegaspargase) / Servier
Enrollment closed: Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage (clinicaltrials.gov) - May 6, 2013
P2, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=57 --> 41 Recruiting --> Active, not recruiting
- hydrocortisone / Generic mfg.
New P2 trial: Effect of Cortisol on Physical Exertion in Patients With Primary Adrenal Failure (clinicaltrials.gov) - May 5, 2013
P2, N=20, Active, not recruiting, Sponsor: Haukeland University Hospital
- imatinib / Generic mfg.
Trial initiation date: AALL01P2: Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 5, 2013
P=N/A, N=126, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Initiation date: Sep 2001 --> Jan 2003
- paclitaxel / Generic mfg.
Enrollment change: Papillary Serous Carcinoma of the Endometrium (clinicaltrials.gov) - May 5, 2013
P2, N=30, Completed, Sponsor: M.D. Anderson Cancer Center
Initiation date: Sep 2001 --> Jan 2003 N=49 --> 30
- | alisertib (MLN8237) / Puma
New P1/2 trial, Combination therapy: Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer (clinicaltrials.gov) - May 5, 2013
P1/2, N=43, Recruiting, Sponsor: Thomas Jefferson University
- linsitinib (ASP7487) / Sling Therap
Enrollment open, Combination therapy: A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma (clinicaltrials.gov) - May 5, 2013
P1/2, N=75, Recruiting, Sponsor: University Health Network, Toronto
N=49 --> 30 Not yet recruiting --> Recruiting
- paclitaxel / Generic mfg.
Trial completion: Papillary Serous Carcinoma of the Endometrium (clinicaltrials.gov) - May 5, 2013
P2, N=30, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | fluticasone / Generic mfg.
New P4 trial: Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis (clinicaltrials.gov) - May 2, 2013
P4, N=60, Recruiting, Sponsor: Azienda Policlinico Umberto I
- | Rituxan (rituximab) / Roche
Enrollment open: Rituximab in Systemic Sclerosis (clinicaltrials.gov) - May 2, 2013
P2/3, N=90, Recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Not yet recruiting --> Recruiting